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Abstract 26 
In the context of inflammation, osteopontin (Opn) is known to promote effector 27 
responses facilitating a pro-inflammatory environment. However, its role during 28 
antigenic tolerance induction is unknown. Using a mouse model of asthma, we 29 
investigated the role of Opn during antigenic tolerance induction and its effects on 30 
associated regulatory cellular populations prior to disease initiation. Our experiments 31 
demonstrate that Opn drives protective antigenic tolerance by inducing accumulation 32 
of interferon (IFN)-β-producing plasmacytoid dendritic cells (pDCs), as well as 33 
regulatory T cells in mediastinal lymph nodes. We also show that recombinant Opn, 34 
and particularly its SLAYGLR motif, in the absence of TLR triggers, directly induces 35 
IFN-β expression in antigen-primed pDCs which renders them extra protective 36 
against induction of allergic airway disease upon transfer into recipient mice. Lastly, 37 
we show that blockade of Type I IFN receptor prevents antigenic tolerance induction 38 
against experimental allergic asthma. Overall, we unveil a new role for Opn in setting 39 
up a tolerogenic milieu boosting antigenic tolerance induction, and thus leading to 40 
prevention of allergic airway inflammation. Our results provide insight for future 41 
design of immunotherapies against allergic asthma. 42 
 43 
44 
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Introduction 45 
Mechanisms of central and peripheral tolerance are crucial for maintaining immune 46 
system homeostasis and preventing exaggerated immune responses to intrinsically 47 
harmless self or foreign antigens. Failure of this mechanism could lead to the 48 
development of chronic inflammation such as allergic asthma and autoimmune 49 
diseases.  50 
As the incidence of allergic disease has risen dramatically, much effort has been put 51 
in determining the control mechanisms of peripheral tolerance to allergens, trying to 52 
find a treatment or prevention strategy for allergic disease. Allergic asthma is a 53 
disease caused by aberrant T helper cell 2 (TH2) immune responses to inhaled 54 
allergens leading to eosinophilic airway inflammation, mucus hyper-secretion and 55 
variable airway obstruction (1). Regulatory T (Treg) cells are important suppressors 56 
of dysregulated TH2 responses to inhaled antigens, as constitutive or induced 57 
deficiency of these cells leads to severe asthmatic reactions(2, 3). Likewise, several 58 
groups have demonstrated that both conventional (c) as well as plasmacytoid (p) 59 
dendritic cells (DCs) are key regulators of TH2 responses in allergic airway 60 
inflammation (4-7). As in many processes of immunoregulation, cytokines like 61 
transforming growth factor-beta 1 (TGF-β1) and interleukin-10 (IL-10) are also 62 
important regulators of tolerance to inhaled antigens (3, 8, 9).  63 
Osteopontin (Opn) is a cytokine expressed by immune cells, such as activated T cells 64 
and DCs, as well as by non-immune cells including tumor cells and stromal cells (10-65 
12). In inflammatory conditions, Opn affects DC function (5, 13-18) and can drive 66 
TH1, TH2 and TH17 effector immune responses (5, 11, 13, 14, 19, 20). On the other 67 
hand, Opn is constitutively expressed by a great variety of cells under non-68 
inflammatory conditions (12, 21-23), but its physiological significance is largely 69 
unknown. For example, secreted Opn (sOpn) is expressed in the bone marrow (BM) 70 
and also upon inflammatory conditions mainly in the form of thrombin-cleaved 71 
fragments (24, 25). Opn fragments have binding motifs for several integrins: the 72 
SLAYGLR motif specifically interacts with integrins α4β1, α9β1 and α4β7, whereas 73 
the RGD motif interacts with the αvβ3, αvβ5, αvβ1 and α5β1 integrins (12, 26). In 74 
addition, the carboxy-terminal half of Opn interacts with certain CD44 variants (12, 75 
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27). Thrombin cleavage of Opn reveals the otherwise cryptic SLAYGLR domain and 76 
this modification is vital for its interaction with α9β1 integrin (28).  77 
 Recent reports show that Opn is expressed in Foxp3+ Treg cells (29, 30) suggesting 78 
its possible role in immune regulation. In the current report, we test whether Opn 79 
affects tolerance induction during intranasal administration of endotoxin-free antigen. 80 
Our results unveil a novel role for Opn as a tolerance enhancer against allergic airway 81 
disease, setting up an immunoregulatory milieu and potentiating CCR7-expressing 82 
pDC recruitment to the draining lymph nodes (dLNs). In addition, we reveal that, in 83 
the absence of PAMPs, sOpn, and specifically its integrin-binding SLAYGLR motif, 84 
induces low levels of IFN-β expression in antigen-primed pDCs. SLAYGLR-treated 85 
pDCs are highly efficient at suppressing allergic airway inflammation via type I IFN. 86 
Finally, we show that Type I interferons are crucial during antigenic tolerance 87 
induction against allergic airway disease.88 
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Materials and methods 89 
Mice. BALB/c, C57BL/6J (designated B6), ovalbumin (OVA)-specific T cell receptor 90 
transgenic C.Cg-Tg (DO11.10)10Dlo/J (designated DO11.10), C.129P2(B6)-IL-91 
10tm1Cgn/J (designated Il10–/–), B6(Cg)-Il10tm1.1Karp (designated Il10GFP), B6.129-92 
Ifnb1tm1Lky/J (designated IfnbEYFP), B6.129S2-Ifnar1tm1Agt/Mmjax (designated 93 
Ifnar1-/-), B6-Tg (C-type lectin domain family 4, member C, CLEC4C- heparin 94 
binding EGF like growth factor, HBEGF) 956Cln/J, designated plasmacytoid 95 
dendritic cell-specific type II C-type lectin (BDCA2)-diphtheria toxin receptor–(DTR) 96 
were purchased from the Jackson Laboratory (Bar Harbor, ME). C57BL/6-Tg Foxp3-97 
DTR/enhanced green fluorescent protein (EGFP), designated depletion of regulatory 98 
T cell (DEREG) mice were provided by Dr. Sparwasser. B6.129S6(Cg)- secreted 99 
phosphoprotein 1 (Spp1)tm1Blh/J, designated Spp1−/− mice were kindly provided by Dr. 100 
Lucy Liaw (Maine Medical Center Research Institute, Scarborough ME). All mice 101 
used in this study were 8- to10-wk old females. Mice were housed at the Animal 102 
Facility of the Biomedical Research Foundation of the Academy of Athens (BRFAA) 103 
and at the University Hospital Gent (Gent, Belgium). Use of mice in this study was 104 
reviewed and approved by the Bioethics Committee of BRFAA, the Veterinarian 105 
Office of Attica and the Animal Ethics Committee of Gent University. All procedures 106 
were in accordance with the US National Institutes of Health Statement of 107 
Compliance (Assurance) with Standards for Humane Care and Use of Laboratory 108 
Animals (A5736–01) and with the European Union Directive 86/609/EEC for the 109 
protection of animals used for experimental purposes.  110 
In vivo experimental protocols. For tolerance induction, mice received 200 μg of 111 
endograde OVA (Hyglos GmbH) (i.n.) in the presence of either 2.5 μg recombinant 112 
Opn protein (rOpn) (R&D Systems) or 72 ng synthetic secreted Opn134-153 fragments 113 
(IVPTVDVPNGRGDSLAYGLR, frOpn) or PBS for control. The RGD domain (Arg-114 
Gly-Asp) of frOpn1 is scrambled to RAA (Arg-Ala-Ala). The SLAYGLR (Ser-Leu-115 
Ala-Tyr-Gly-Leu-Arg) of frOpn2 is scrambled to LRAGLRS (Leu-Arg-Ala-Gly-Leu-116 
Arg-Ser). The frOpn3 has both the RGD and SLAYGLR scrambled to RAA and 117 
LRAGLRS, respectively (Caslo Laboratory ApS). Opn oligopeptide fragments have 118 
been previously described(31). Myelin oligodendrocyte glycoprotein peptide 119 
(MOG)35–55 peptide (MEVGWYRSPFSRVVHLYRNGK) (Caslo Laboratory ApS) 120 
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was also used for tolerance induction (250 μg/mouse i.n.). Mice were euthanized 36-121 
40 hrs later and analyzed. In certain experiments, tolerance was induced prior to 122 
allergic airway disease induction: mice received 200 μg of endograde OVA (i.n.) on 123 
days -2, -1 and 0 in the presence of either 2.5 μg of rOpn or 72 ng of frOpn1-3 124 
synthetic fragments (i.n.). Control mice received PBS. Allergic airway disease 125 
(asthma) was subsequently induced: on day 10, mice were immunized with chicken 126 
OVA Grade V (Sigma-Aldrich) (50 μg) in 0.2 ml aluminium hydroxide (alum) 127 
(Serva) followed by 3 challenges with 5% aerosolized OVA between days 16-18 as 128 
described(5, 15). Mice were euthanized 2 d after the last aerosol (on day 20). DEREG 129 
mice received 1μg of diphtheria toxin (DT, Sigma-Aldrich) 35 or PBS, i.p. on days -3 130 
and -2 (6 hrs prior to i.n. OVA administration). For DT control group, non Tg 131 
littermates were administered DT. For pDC depletion, mice received 225 μg of 120G8 132 
pDC-depleting Ab (IgG2a-Dendritics, Lyon, France) (32) or Ig an isotype control Ab 133 
i.p., daily, on days -6, -5, -4 and -3. As in Fig. 4A, on days -2, -1 and 0, mice received 134 
i.n. 200 μg of OVA endograde along with 2.5 μg of rOpn and euthanized 7 days later. 135 
For pDC depletion in BDCA2-DTR mice 120 ng/mouse of DT was administered i.p. 136 
on days -4 and -3 in the 7-day tolerance induction protocol (as in Fig. 4A) (33). 137 
Efficient pDC depletion from dLNs in both approaches was determined by FACS 138 
analysis as ≥95% (data not shown). For neutralization of IFNAR1 mice received 20 139 
μg i.p. of a polyclonal affinity-purified neutralizing Ab to mouse IFNAR1 (clone 140 
MAR1-5A3) (eBioscience) or goat IgG isotype control (R&D Systems) 2 hrs before 141 
tolerance induction. After IFNAR1 neutralization and tolerance, for allergy induction 142 
mice were immunized with chicken OVA on day 15, and OVA challenges were 143 
performed between days 21-23. 144 
Penh. Lung function was measured in mice 24 hrs after the final OVA challenge (day 145 
19) by whole body plethysmography (Buxco Technologies) in order to calculate 146 
enhanced pause (Penh). Responses to inhaled methacholine (Sigma Aldrich) at 147 
concentrations of 3–100 mg/ml were measured for 1 min, as previously described(5). 148 
Analysis of Bronchoalveolar lavage (BAL) and lung histology. BAL harvesting 149 
and analysis was performed as previously described (34, 35). For histological 150 
analysis, paraffin-embedded (4μm) lung sections were stained with haematoxylin & 151 
eosin (H&E) and quantified as previously described (34). Goblet cells were quantified 152 
on Periodic-Acid-Schiff (PAS)-stained lung sections (5). A semi-quantitative scoring 153 
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system was used to grade the size of lung infiltrated as previously described (36). 154 
Goblet cells were counted on PAS stained sections using an arbitrary scoring system 155 
as previously described(36). 156 
pDC generation from BM, cultures and adoptive transfer. For pDC generation, 157 
bone marrow (BM) cells were isolated and cultured with rhFlt3L as described(37). On 158 
day 11, 7AAD-CD3-CD19-CD11c+B220+PDCA1+Siglec-H+ pDCs were sorted using 159 
FACS ARIAIII to a purity ≥98% after enrichment with CD11c microbead kit 160 
(Miltenyi Biotec). Sorted pDCs from BM-cultures cultured were conditioned for 16 161 
hrs with 100 μg/ml of endograde OVA or LoToxTM Dermatophagoides pteronyssinus 162 
allergen 1 (Derp1) (Indoor Biotechnologies) in the presence of 250 ng/ml rOpn or 163 
18.2 ng/ml frOpn1 or frOpn3 or PBS. After the culture with OVA, pDCs were washed 164 
and analysed or transferred intravenously (i.v.) via the tail vein (106/mouse). Allergic 165 
asthma was induced in mice 7 days later. Mice were euthanized 2 d after the last OVA 166 
challenge (Fig. 7B, 10A). 167 
Cell culture, proliferation and cytokine analysis. Isolated dLN cells (2x105 to 106) 168 
were cultured with 125 μg/ml OVA (Sigma-Aldrich) for 48 h. We performed 169 
proliferation assays with thymidine incorporation, as previously described(38). For 170 
certain experiments, proliferation of cells was measured as % of Edu+ cells by FACS, 171 
using a Molecular Probes kit. For cytokine measurements, we used ELISA kits for IL-172 
5 and IFN-γ (BD Biosciences); IL-4, IL-13 (R&D Systems) and IFN-β (BioLegend).  173 
Flow cytometry. Freshly isolated live (7AAD–, BD Biosciences) dLN cells and in 174 
vitro BM-derived cells were stained with combinations of fluorochrome-conjugated 175 
Abs to CD4-Pacific Blue or -PE/Cy5 (clone GK 1.5), CD3-PE/Cy7 or -PE/Cy5 or -PE 176 
or-FITC (17A2), CD11c-PE/Cy7 or -FITC or Orange 605 (N418), CD11b-PE/Cy7 or 177 
-FITC (M1/70), B220-PE or -BV 510 (RA3-6B2), CCR7-PE (4B12), Siglec-H-178 
Pacific Blue or -FITC (551), PDCA-1-PE or -FITC (927), CD19-PE/Cy7 or -PE/Cy5 179 
(6D5), CD25-PE (PC61.5) (BioLegend) and T1ST2 (DIH9) (-FITC, MD Biosciences 180 
or -PE BioLegend). For intra-nuclear staining of Foxp3, permeabilization kit and 181 
antibody (-Pacific Blue or -PE/CyC5, clone FJK-16s) were used (eBioscience). The 182 
flow cytometric measurements were performed using Attune Acoustic Focusing 183 
Cytometer (Applied Biosystems) and FACS ARIAIII (BD). FACS sorting of pDCs 184 
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was performed using FACS ARIAIII. Data analysis was performed by Flow-Jo 185 
Software (Tree Star).  186 
Chemotaxis assay. Sorted pDCs from LNs and spleen of BALB/c mice, were treated 187 
with rOpn (500 ng/ml) for 18-20 h and assayed for migration in response to 188 
chemokines CCL19 or CCL21 (200 ng/mL) (R&D Systems). The lower chambers of 189 
Transwell plates (QCMTM 5.0-μm chemotaxis assay 24-well-Colorimetric, Millipore) 190 
were filled with 500 μl serum-free medium in the presence or absence of chemokines. 191 
DCs (105 cells per 200 μl) resuspended in serum-free medium were deposited in the 192 
upper chambers of the Transwell plates and allowed to migrate for 4 h at 37°C in 5% 193 
CO2. For each experiment pooled total cells from spleen, inguinal and mesenteric 194 
lymph nodes of mice (n=8) were used and pDCs were isolated by sorting. 195 
Suppression assay, Treg cell induction in vitro. BM-derived pDCs pre-treated with 196 
±OVA and ±rOpn were cultured with naive DO11.10 CD4+ T cells for 3 d at a 1:5 197 
ratio. T cells were harvested and cultured without OVA in the presence of 1 ng/ml 198 
recombinant mouse IL-2 (R&D) for additional 7 d. Suppressive activity was assayed 199 
on 105 freshly purified CFSE (Invitrogen) labelled DO11.10 CD4+ T cells stimulated 200 
with 104 irradiated BALB/c splenocytes, with 1 μg/ml OVA323-339 peptide (Caslo 201 
Laboratory ApS), in the presence or absence of 105 DC-stimulated T cells. CFSE 202 
uptake was assayed 7 d later (Fig. 7A). 203 
Quantitative RT-PCR analysis. Total RNA was extracted from cells isolated from 204 
dLNs with anti-mPDCA-1 and CD11c MicroBeads (Miltenyi Biotec) and further 205 
purified with FACS sorting. cDNA synthesis described(31). Primers were designed 206 
using the Primer3 program and are depicted in Supplemental Table 1 (MWG 207 
Eurofins). Hypoxanthine-guanine phosphoribosyl transferase (Hprt), Foxp3, Il-10, 208 
Il27p28 and Spp1 primers were previously described (31). Real-time PCR was 209 
performed and analyzed as previously described (31). The reference gene used for 210 
real-time PCR analysis is Hprt. 211 
Statistical Analysis. Data were analyzed using Prism 7 Software (GraphPad). The 212 
two-tailed Student’s t-test was used for statistical analyses of two-group comparisons. 213 
Multigroup comparisons were performed by a two-way analysis of variance 214 
(ANOVA) followed by the Bonferroni correction for the multiplicity of tests. All 215 
results are presented as mean ± standard error of the mean (SEM). In all experiments, 216 
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statistical significance was defined as: *P≤0.0332; **P≤0.0021; ***P≤0.0002, 217 
****P< 0.0001.218 
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Results 219 
Opn boosts antigenic tolerance leading to increased protection from allergic 220 
airway disease 221 
To address whether Opn plays a role in tolerance induction, mice received i.n. 222 
endotoxin-free chicken OVA together with endotoxin-free rOpn or PBS for control, 223 
and protection against disease was assessed by utilizing a well-established model of 224 
allergic asthma (39) (Fig. 1A). OVA-tolerized mice showed a significant decrease in 225 
BAL, total cells and eosinophils, as well as lung tissue inflammatory scores and 226 
mucus secretion (Fig. 1B-C), compared to non-tolerized mice. In addition, enhanced 227 
pause (Penh) in OVA-tolerized mice was significantly reduced (Fig. 1D). 228 
Importantly, in OVA/rOpn-tolerized mice, numbers of eosinophils in BAL (Fig. 1B), 229 
airway hyperresponsiveness (AHR) (Fig. 1D), lung leukocytic infiltration and mucus 230 
secretion (Fig. 1C) were further reduced compared to OVA-tolerized mice. 231 
Furthermore, OVA/rOpn tolerization resulted in significantly reduced levels of IL-4, 232 
IL-13 and IFN-γ in the BAL, as well as in reduction of OVA-specific responses in 233 
mediastinal lymph node (mLN) cell cultures, and in TH cell proliferation compared to 234 
OVA-tolerization (Fig. 1E-G). Studies from our group and others have shown that 235 
there are high levels of IFN-γ production in allergic airway disease (5, 15, 40-42). The 236 
above findings indicated that administration of Opn along with OVA promotes 237 
enhanced tolerance, conferring significant protection from disease development. 238 
We next investigated whether Opn deficiency had any effect on tolerance induction. 239 
Tolerance induction in Spp1–/– mice was not as effective as in Spp1+/+, since we noted 240 
no significant change in neither number of eosinophils nor total cell numbers in BAL 241 
(Fig. 2A). In accordance, tolerogenic i.n. OVA administration in Spp1–/– mice could 242 
not efficiently dampen the inflammation and mucus secretion in the lung, whereas it 243 
was very efficient in Spp1+/+ mice (Fig. 2B). TH2 cytokine production by OVA–244 
stimulated mLN cells was also lower in OVA-tolerized Spp1–/– compared to PBS-245 
treated Spp1-/- mice (Fig. 2C). OVA–stimulated mLN cells from OVA-tolerized 246 
Spp1+/+ mice produced approximately 50% lower levels of TH2 cytokines, compared 247 
to cells from PBS-treated Spp1+/+ mice. Whereas, OVA-tolerized Spp1–/– mice had a 248 
lower reduction in cytokine levels compared to Spp1+/+ (Fig. 2C). The reduction in 249 
IFN-γ levels was similar among groups (Fig. 2C). Finally, OVA tolerization of Spp1–250 
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/– mice showed less decrease in the percentages of CD3+ T proliferating cells in 251 
cultures of mLN cells, compared to those from Spp1+/+ OVA-treated mice (Fig. 2D). 252 
The above results strongly support that in the presence of Opn, tolerance induction is 253 
more effective.  254 
Opn administration along with antigen increases accumulation of tolerogenic 255 
pDCs 256 
Migratory non-lymphoid tissue DCs transporting antigens to LNs are involved in 257 
promoting tolerance to self-antigens at steady state. As pDCs constitute a tolerogenic 258 
DC subset(43-47) and Opn has a dual role in the recruitment of DC subsets(5), we 259 
analyzed pDC numbers in the dLNs of OVA-tolerized mice and PBS-treated controls 260 
(Fig. 3A). Numbers of dLN pDCs were increased in OVA-treated group compared to 261 
the PBS control group (Fig. 3B). Mice treated with OVA/rOpn had increased 262 
percentages and significantly higher total numbers of pDCs in the dLNs at 36-40 hrs 263 
following treatment compared to OVA treatment (Fig. 3B). On the other hand, cDC 264 
numbers in the dLNs of OVA/rOpn mice were significantly reduced and percentages 265 
were lower compared to OVA treatment alone (Fig. 3B). Therefore, administration of 266 
Opn during tolerance induction affects the balance of DC subsets in the dLNs by 267 
increasing the numbers of pDCs and reducing the numbers of cDCs. 268 
The importance of Opn for DC subset recruitment in tolerance was also demonstrated 269 
using Opn deficient mice. Antigenic tolerance induction in Spp1–/– mice resulted in 270 
significant reduction in pDC numbers in their dLNs, compared to Spp1+/+ mice 271 
(Supplemental Fig. 1). At the same time, cDC numbers were significantly increased 272 
in the dLNs of Spp1–/– mice (Supplemental Fig. 1). Conclusively, these results show 273 
that tolerogenic administration of OVA in an Opn efficient microenvironment 274 
enhances pDC accumulation in the dLNs. 275 
Administration of Opn during tolerance induction regulates CCR7 expression 276 
affecting DC subset homing to dLNs 277 
To explore the reason for the increased numbers of pDCs in the dLNs of Opn treated 278 
mice, we investigated the effect of Opn on CCR7+ pDCs. CCR7 is a chemokine 279 
receptor responsible for homing of DCs to dLNs (48-50). We quantified CCR7+ DC 280 
subsets in peripheral blood, 36 hrs following OVA/rOpn tolerogenic administration 281 
12 
 
(Fig. 3A). Percentages of CCR7+ pDCs per total pDC numbers were significantly 282 
elevated in peripheral blood of mice treated with rOpn during tolerance induction 283 
compared to PBS treated mice (Fig. 3C). Percentages of CCR7+ cDC per total cDC 284 
numbers originating from peripheral blood of mice that had been administered 285 
OVA/rOpn were significantly decreased, compared to OVA-administered ones (Fig. 286 
3C). Our results demonstrate that Opn leads to enhanced migratory CCR7+ pDC 287 
percentages per total pDCs in the blood.  288 
We also found that OVA/rOpn-administered mice had significantly higher levels of 289 
Ccl19 and Ccl21 (encoding CCL19 and CCL21 chemokines that bind to CCR7) 290 
expression in their dLNs compared to OVA-administered mice (Fig. 3D), possibly 291 
attracting the increased numbers of CCR7+ pDCs to dLNs. Indeed, in vitro 292 
transmigration assays showed that sorted pDCs from naïve mice, pre-treated with 293 
rOpn had a 2-fold increase in CCL19-induced chemotaxis compared to PBS-treated 294 
pDCs (Fig. 3E). The above findings demonstrate that during tolerance induction, Opn 295 
can differentially regulate percentages of CCR7+ DC subsets, therefore affecting their 296 
chemotactic migration to the dLNs in favor of pDCs. Moreover, the observed 297 
increased gene expression of the CCR7 ligands, CCL19 and CCL21, provide an extra 298 
explanation for the rOpn-mediated migration of pDCs to the dLNs.  299 
Opn enhances pDC-dependent Foxp3+ Treg cell accumulation and promotes an 300 
immunoregulatory milieu in the dLNs 301 
As antigen administration for tolerance induction leads to generation of Treg cells 302 
(51), we investigated whether Opn had an effect early on this process. We 303 
administered i.n. OVA along either rOpn (OVA/rOpn) or PBS in mice for three 304 
consecutive days. One week later, mice were analyzed (Fig. 4A). OVA/rOpn treated 305 
mice showed almost a 2-fold increase in the percentages, as well as in total numbers 306 
of CD4+Foxp3+ Treg cells in the dLNs, compared to OVA-treated mice (Fig. 4B). 307 
Increased numbers of Foxp3+ Treg cells in OVA/rOpn tolerized mice, were 308 
accompanied by significantly enhanced Foxp3 expression in dLN cells (Fig. 4C). In 309 
addition, OVA/rOpn treatment also induced significant increase in the expression 310 
levels of immunoregulatory molecules such as Il10, Ido, Tgfb1, Fgl2 and Il27 in the 311 
dLNs compared to OVA treatment (Fig. 4C). Conclusively, Opn administration along 312 
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with antigen promotes Foxp3+ Treg cell accumulation resulting in a highly tolerogenic 313 
microenvironment in the dLN. 314 
To directly test whether increased numbers of Foxp3+ Treg cells mediate the observed 315 
rOpn-promotion of tolerance, we depleted Foxp3+ Treg cells prior to tolerance 316 
induction using DEREG mice (52) (Fig. 5A). Induction of tolerance with rOpn could 317 
not protect Treg-depleted mice which exhibited increased allergic responses as 318 
demonstrated by increased eosinophilia and lymphocytosis in the BAL, increased T 319 
cell proliferation, lung inflammation with mucus production and OVA specific 320 
cytokine responses, compared to Treg efficient mice (Fig. 5B-E).  321 
To address whether the Opn-mediated increase in pDC numbers was responsible for 322 
the observed accumulation of Foxp3+ Treg cells, we depleted pDCs by administering 323 
120G8 pDC-depleting antibody(32) prior to induction of tolerance and examined the 324 
accumulation of Foxp3+ Treg cells in the dLNs. This depletion led to a significant 325 
reduction in CD4+Foxp3+ Treg cell numbers versus OVA/rOpn administration in non-326 
pDC-depleted mice (Fig. 6A), resulting in exacerbated allergic airway disease (Fig. 327 
6B). We observed similar effects of rOpn on Treg cellularity in LNs after in vivo 328 
depletion of pDCs in BDCA2-DTR transgenic mice (33) (Supplemental Fig. 2). Thus, 329 
Opn-mediated pDC accumulation is at least partially responsible for the higher 330 
numbers of Treg cells in dLNs. In addition, dLN cells from OVA/rOpn-treated pDC-331 
depleted mice were significantly less capable of suppressing OVA-specific T cell 332 
proliferation (Fig. 6C), compared to dLN cells from OVA/rOpn-treated non-pDC-333 
depleted mice, reaching even lower suppressive ability than that of OVA-treated 334 
pDC-depleted dLN cells. Thus, OVA/rOpn treatment increased numbers of pDCs 335 
favoring accumulation of Foxp3+ Treg cells that are crucial for tolerance maintenance. 336 
Opn treatment of pDCs increases their suppressive activity against allergic 337 
airway disease 338 
We tested the suppressive function of in vitro OVA/rOpn-treated BM-derived pDCs 339 
by co-culturing them with CD4+ T cells. T cells obtained from OVA/rOpn-treated 340 
pDC cultures significantly suppressed responses of DO11.10 T cells to OVA 341 
compared to T cells obtained from OVA-treated pDC cultures (Fig. 7A). 342 
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We also adoptively transferred BM-derived pDCs, pre-conditioned in vitro with OVA 343 
or OVA/rOpn, into recipient mice prior to induction of allergic airway inflammation 344 
(Fig. 7B). Control mice received PBS-treated pDCs. Total and eosinophil cell 345 
numbers, as well as lung tissue inflammatory scores and mucus secretion were lower 346 
in BAL of OVA/rOpn-treated pDC recipient mice compared to OVA-treated pDC 347 
recipient mice (Fig. 7B-C). Furthermore, OVA/rOpn-treated pDC recipients had 348 
significantly reduced OVA-specific responses compared to OVA-treated pDC 349 
recipients (Fig. 7D). Thus, OVA/rOpn treatment of pDCs rendered them more 350 
regulatory, indicating that Opn affects the intrinsic tolerogenic function of pDCs. 351 
Opn SLAYGLR motif is responsible for pDC recruitment and effective 352 
protection from allergic disease  353 
RNA expression analysis revealed that, upon stimulation, mLN pDCs elevate 354 
expression of integrins αvβ3, α4β1 and α9β1 (data not shown). As the SLAYGLR 355 
motif of Opn interacts with α4β1, α4β7 and α9β1 integrins (12), and the RGD motif 356 
interacts with the αvβ3 integrin (11, 12), we asked which Opn domain is responsible 357 
for the observed effects on pDCs during tolerance induction. Thus, the synthetic 358 
frOpn134-153, containing the RGD and the SLAYGLR integrin binding motifs either 359 
intact or scrambled (31), were used with OVA to induce tolerance in mice, allowing 360 
us to unveil the involvement of the different integrin-binding motifs of Opn in pDC 361 
recruitment (Fig. 8A). The frOpn134-153 represents the thrombin cleaved fragment of 362 
Opn that reveals the otherwise cryptic domain SLAYGLR (28). OVA/frOpn1, 363 
containing an intact SLAYGLR motif but a scrambled RGD motif, induced 364 
accumulation of higher numbers of pDCs in the LNs compared to OVA, and 365 
OVA/rOpn (Fig. 8A). Conversely, frOpn2, which contains an intact RGD, but a 366 
scrambled SLAYGLR motif induced a reduction in pDC cell numbers in dLNs 367 
compared to all other treatments (Fig. 8A). When both motifs were scrambled as in 368 
the case of frOpn3, the numbers and percentages of pDCs were not significantly 369 
altered compared to OVA (Fig. 8A, Supplemental Fig. 3Α). OVA/frOpn1 induced 370 
higher percentages of pDCs in the dLNs compared to OVA and OVA/frOpn3 371 
(Supplemental Fig. 3A). These data revealed that the Opn SLAYGLR motif is 372 
responsible for pDC accumulation into dLNs. These data also reveal that the RGD 373 
motif suppresses this accumulation. 374 
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To examine the in vivo tolerogenic potential of frOpn1 in allergic disease, mice were 375 
treated with OVA together with either frOpn1 or frOpn3 for control before the 376 
induction of allergic airway inflammation (Fig. 8B). OVA/frOpn1 was more 377 
successful than OVA/frOpn3 in promoting tolerance and thus protecting mice against 378 
allergic airway inflammation as demonstrated by lower Penh values (Fig. 8C). BAL 379 
eosinophilia, as well as inflammatory score and mucus staining were also dampened 380 
after OVA/frOpn1 treatment (Fig. 8D). In addition, treatment with OVA/frOpn1 led 381 
to reduced levels of OVA-specific responses (Fig. 8E) and numbers of T1ST2+CD4+ 382 
T cells in the dLNs (Fig. 8D). Collectively, this dataset indicates that the Opn 383 
SLAYGLR motif significantly boosts tolerance. 384 
Opn SLAYGLR motif induces IFN-β expression in pDCs 385 
We further asked whether OVA/frOpn1 treatment affects in vivo pDC immune profile 386 
36-40 hrs after tolerance induction (Fig. 3A). In vitro, OVA/frOpn1 conditioning of 387 
pDCs promoted a 2-fold increase in Ifnb mRNA expression at 16 hrs (Fig. 9A). The 388 
observed difference in Ifnb expression was also reflected in the amount of IFN-β 389 
secreted, that was 5-fold higher in OVA/frOpn1-conditioned pDCs compared to 390 
OVA/frOpn3 (Fig. 9B). House dust mite endotoxin-free Derp1 was also used to test 391 
whether the increased IFN-β response could be observed using another allergen. 392 
Indeed, Derp1/frOpn1 in vitro conditioning of pDCs resulted in higher Ifnb expression 393 
compared to Derp1/frOpn3 (Fig. 9C). We also measured higher levels of Ifnb 394 
expression in OVA/rOpn-conditioned pDCs compared to OVA/PBS (Supplemental 395 
Fig. 3B).  396 
As RNA expression analysis revealed that mLN pDCs from in vivo OVA/frOpn1 397 
treatment had elevated Ifnb (data not shown), we found that indeed Ifnb expression 398 
was upregulated in these cells (Fig. 9E). To confirm the changes in IFN-β expression 399 
in vivo, we used IFN-βEYFP reporter mice. OVA/frOpn1-tolerized mice had 400 
significantly increased numbers of IFN-βEYFP+ pDCs and higher IFN-β expression per 401 
pDC (MFI) compared to OVA/frOpn3 (Fig. 9D). To test whether this effect is 402 
relevant to the antigen used, we tolerized IFN-βEYFP mice with a self-antigen, the 403 
MOG35-55, with frOpn1 or frOpn3. MOG35-55/frOpn1 administration in IFN-βEYFP 404 
mice resulted in significantly increased accumulation of IFN-βEYFP+ pDCs, as well as 405 
IFN-β expression per pDC (MFI) in LNs (Fig. 9F). However, the increase here was 406 
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modest compared to Opn/OVA, possibly because MOG is a peptide. These results 407 
suggest that under tolerogenic conditions, Opn SLAYGLR motif can boost Ifnb 408 
expression in pDCs through a mechanism independent of the antigen used. 409 
Opn/SLAYGLR-induced IFN-β in pDCs is protective against allergic disease 410 
pDCs were primed in vitro with endotoxin-free OVA and frOpn1 or frOpn3 and 411 
transferred into mice prior to induction of allergic airway inflammation (Fig. 10A). 412 
Recipient mice were Ifnar1+/+ or Ifnar1-/-. pDCs treated with frOpn1 were 413 
significantly more potent in protecting Ifnar1+/+ mice against allergic airway 414 
inflammation, as demonstrated by reduced lung airway inflammation, BAL 415 
eosinophilia and goblet cell hyperplasia compared to control and OVA group (Fig. 416 
10A). Similar enhanced protection was also observed when pDCs were treated with 417 
rOpn and adoptively transferred into Ifnar1+/+ mice (Fig. 7B-D). Actually, type I IFN 418 
produced by pDCs was crucial in maintaining this protective effect, as Ifnar1–/– 419 
recipient mice were not protected against allergic asthma (Fig. 10A). These results 420 
demonstrate that the integrin-binding SLAYGLR domain of Opn renders pDCs more 421 
regulatory through type I IFN production in the context of allergic airway 422 
inflammation. In fact, pDCs cannot preserve their regulatory function in recipients 423 
that lack expression of type I IFN receptor. Finally, neutralization of IFNAR1 during 424 
the OVA tolerance induction phase (Fig. 10B) resulted in reduced protection from 425 
allergic airway disease concomitant with increased eosinophilia in BAL (Fig. 10C) 426 
and increased OVA-specific responses (Fig. 10D). This indicates that type I IFN is 427 
absolutely necessary for effective antigenic tolerance induction in this context.428 
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Discussion 429 
In the current report, we unveil a new role for Opn, and particularly its SLAYGLR 430 
motif, in setting up a tolerogenic milieu driving antigenic tolerance induction, and 431 
thus leading to prevention from allergic airway inflammation.  432 
The respiratory mucosa is constantly being exposed to a myriad of non-pathogenic 433 
environmental antigens. To protect against the immunopathological consequences of 434 
this constant stimulus, a default low non-inflammatory TH2 mechanism and/or a T 435 
cell-mediated tolerance mechanism is activated (53). The mechanism underlying these 436 
processes is not fully understood. In the present study, we initially demonstrate that 437 
Opn induces tolerance by tilting the pDC/cDC balance in favor of the anti-438 
inflammatory pDCs, via differentially regulating their CCR7 expression. CCR7-439 
dependent homing of DCs into the dLNs is required for the induction of tolerance(50).  440 
Opn promotes Th2 effector responses when administered during the allergen 441 
sensitization phase (5). In contrast, we have previously shown that Opn inhibits Th2 442 
responses during allergen challenge and administration of rOpn during that phase is 443 
suppressive for experimental allergic asthma (5). Here, we explore the role of Opn 444 
during a different phase, which is when antigen is administered during tolerance 445 
induction, prior to sensitization. Thus, Opn is administered, prior to sensitization 446 
phase, along with the allergen (antigen) intranasally, in order to test its effects upon 447 
antigenic tolerance induction. Together, our results in this manuscript as well as in 448 
previous studies (5) show that administration of Opn during (a) antigenic tolerance 449 
induction, and (b) antigenic challenge, is protective and can thus be used as either a 450 
preventive, or a therapeutic agent against allergic airway disease. 451 
Regulatory cytokines such as Tgfb1, Il10, Fgl2, and molecules such as Ido (54) were 452 
substantially up-regulated in our Opn-driven tolerance model, creating an 453 
immunoregulatory microenvironment in the dLN. This tolerogenic milieu was 454 
accompanied by accumulation of Foxp3+ Treg cells, which are very important for 455 
induction of tolerance (51). Mice that had enhanced Treg cell numbers, due to rOpn 456 
administration, showed suppressed effector responses and were protected from 457 
allergic disease. When Foxp3+ Treg cells were depleted, Opn-mediated tolerance 458 
boosting was abolished. In light of its well-established pro-inflammatory function 459 
(10-12), it was unexpected that Opn could be an inducer of Treg cell accumulation in 460 
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vivo. In the absence of pDCs, rOpn administration was no longer capable to induce 461 
increased numbers of Foxp3+ Treg cells in the dLNs, demonstrating that rOpn affects 462 
Treg numbers mainly through its impact on pDCs. On the other hand, after tolerance 463 
induction without addition of Opn, Treg cell numbers do not appear to depend on 464 
pDCs, as pDC depletion did not reduce their numbers. These results show that rOpn 465 
conditions pDCs to enhance Treg cell accumulation. Functional flexibility and 466 
fostering of regulatory T cell responses are typical features of pDC involvement in 467 
tolerance (4, 46), as also revealed by our studies. 468 
Thrombin cleavage of Opn occurs during both homeostatic and inflammatory 469 
conditions (24, 25) and conformational changes after thrombin cleavage result in 470 
higher affinity binding to certain receptors (26). In fact, the cryptic SLAYGLR motif 471 
is revealed upon thrombin cleavage of Opn which is vital for its interaction with α9β1 472 
integrin (28). As the SLAYGLR motif of Opn protein interacts with α4β1, α4β7 and 473 
α9β1 integrins (12), and the RGD motif interacts with the αvβ3 integrin (11, 12), we 474 
used the synthetic frOpn134-153, containing both integrin binding motifs either intact or 475 
scrambled (31). Thrombin cleavage of Opn also produces a fragment containing the 476 
carboxy-terminal half of Opn, which interacts with certain CD44 variants (12, 27). In 477 
our settings, as well as in other settings (31, 55, 56), frOpn134-153 has a greater 478 
efficiency compared to full length Opn. It is thus possible that interaction of Opn with 479 
CD44 interferes with certain Opn effects, such as pDC recruitment. Future 480 
investigation will elucidate the role of Opn-CD44 interaction in tolerance induction. 481 
Under endotoxin-free conditions, we demonstrated that the SLAYGLR domain of 482 
Opn (frOpn1) enhances IFN-β expression in pDCs exposed to protein or peptide 483 
antigen. Accordingly, we showed that adoptively transferred OVA/frOpn1-treated 484 
pDCs were more efficient at suppressing allergic airway inflammation in recipient 485 
mice. This regulatory function was indeed mediated by the observed upregulated 486 
production of IFN-β by pDCs, as Ifnar1–/– recipient mice were not protected against 487 
allergic asthma. During the course of allergic airway inflammation, pDCs as well as 488 
their type I IFN production are suppressive for disease (4, 57-59). Our studies reveal 489 
that pDCs expressing higher IFN-β levels due to exposure to Opn are important for 490 
protective tolerance prior to disease induction. Importantly, our experiments point to a 491 
crucial role of type I IFNs during the induction of efficient anti-allergic antigenic 492 
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tolerance. Accordingly, IFNAR signalling promotes Treg cell development and 493 
function under stress conditions (60). 494 
Opn administered during tolerance also resulted in a remarkable up-regulation of the 495 
ligands of CCR7, CCL19 and CCL21 in dLNs, reminiscent of that observed in 496 
tumors(61). Specifically, CCL21 high expression by melanoma in mice was 497 
associated with an immunotolerant microenvironment, which included the induction 498 
of lymphoid-like reticular stromal networks, an altered cytokine milieu, and most 499 
importantly the recruitment of regulatory leukocyte populations(61). High Opn 500 
expression is prevalent in many types of malignancy(62), and although Opn is 501 
considered pro-inflammatory, most of these tumors escape immune surveillance. 502 
Thus, it is possible that Opn and its mediated induction of CCL21 could also be 503 
involved in suppression of anti-tumor immunity. 504 
In this report, we demonstrate that the SLAYGLR motif of sOpn is enhancing 505 
regulatory mechanisms when administered together with endotoxin-free antigen in a 506 
tolerogenic context. In this respect, Opn has a unique effect on immunity, differing 507 
substantially from its effects in the presence of danger signals. The SLAYGLR motif 508 
of Opn interacts with integrins(12). Addressing which integrin mediates the 509 
tolerogenic effects of the SLAYGLR motif of Opn on Ag-loaded pDCs, and mainly 510 
the induction of IFN-β, will assist in the design of therapies targeting tolerance in 511 
allergy. Finally, our results point to novel effects of Opn on Foxp3+ Treg cells that 512 
remain to be explored.513 
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Figure legends 718 
Figure 1. Opn administration boosts antigenic tolerance leading to increased 719 
protection from allergic airway disease. (A) Experimental protocol utilized for 720 
endotoxin free-tolerance (OVA administration) induction followed by allergic asthma 721 
induction. Controls were mice pre-treated with PBS (no tolerance) and subsequent 722 
allergic airway disease induction (white bars). Controls for allergic airway disease 723 
were mice pre-treated and sensitized with PBS. (B) Total cell counts in (BAL) and 724 
eosinophils. (C) Representative photomicrograph of H&E and PAS stained lung 725 
sections and histological scores. Scale bar, 100 µm. (D) AHR responses depicted as 726 
(Penh) in day 19. (E) Levels of IL-4, IL-13 and IFN-γ in BAL and (F) in the 727 
supernatant of mLN cells stimulated ex-vivo with OVA. (G) [3H]-thymidine 728 
incorporation of mLN cells stimulated ex-vivo with OVA. Different wells of pooled 729 
mLN cells cultured in E, F, G. Values are expressed as mean ± standard error of the 730 
mean (SEM, n=8 mice per group), one representative of three independent 731 
experiments.  732 
Figure 2. Spp1–/– mice are more resistant to tolerance induction. Spp1–/– or Spp1+/+ 733 
mice received three doses of endotoxin-free OVA or PBS i.n. on days -2, -1 and 0 as 734 
in Fig. 1A. On day 10, mice were sensitized i.p. with OVA in alum and were 735 
subsequently challenged through the airways with aerosolized OVA between days 16-736 
18. Analysis was performed on day 20. (A) Differential eosinophil and total cell 737 
counts in BAL, (B) lung inflammation shown in H&E stained sections and mucus 738 
secretion shown in PAS stained sections from PBS and OVA-treated Spp1+/+ and 739 
Spp1–/– mice are shown. Scale bar, 100 µm. (C) Levels of IL-4, IL-5, IL-13 and IFN-γ 740 
in supernatants of OVA-stimulated dLN cells and (D) percentages of Edu+CD3+CD4+ 741 
T in OVA-stimulated dLN cells of both mice groups. Different wells of pooled mLN 742 
cells cultured in C and D. Values are expressed as mean ± SEM (n=6 mice per group), 743 
one representative of three independent experiments. 744 
Figure 3. Opn-induced accumulation of pDCs in the dLN and differential CCR7 745 
expression. (A) Treatment of mice with endotoxin free OVA (tolerance induction) 746 
together with endotoxin free rOpn, or PBS for B-D. Controls (without tolerance) were 747 
the PBS-treated mice (white bars). (B-D) 7AAD–CD3–CD19–CD11c+PDCA-1+CCR7+ 748 
pDCs and 7AAD–CD3–CD19–CD11c+CD11b+CCR7+ cDCs quantified in dLNs by 749 
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flow cytometry. (B) Representative percentages in flow cytometric plots and numbers 750 
of dLN pDCs (upper panel) and cDCs (lower panel). (C) Representative flow 751 
cytometric plots and percentages of peripheral blood CCR7+ pDCs and cDCs among 752 
total pDCs and cDCs respectively and (D) relative expression to Hprt of Ccl19 and 753 
Ccl21 in dLNs of tolerized mice. Values are expressed as mean ± SEM (n=10 mice 754 
per group and cDNAs were pooled from three separate experiments). (E) Sorted 755 
pDCs from LNs and spleens of naïve BALB/c mice were pulsed with vehicle or rOpn 756 
for 24 hrs and were then subjected to transmigrate in response to CCL19. Numbers of 757 
migrating PBS (white bars) or rOpn treated-pDCs (black bars) are depicted. Triplicate 758 
wells of pooled pDCs sorted from spleens and LNs (n=8). Values are expressed as 759 
mean ± SEM (n=5-8 mice per group), one representative of five independent 760 
experiments in A-C and from three in E.  761 
Figure 4. Opn administration with antigen promotes accumulation of Treg cells 762 
and immunoregulatory gene expression in dLNs. (A) Tolerance induction in mice 763 
received 3 doses of endotoxin free OVA along with rOpn or PBS. Controls (without 764 
tolerance) were PBS-treated mice (white bars). (B) Percentages and numbers of 765 
CD3+CD4+Foxp3+ T cells quantified in dLNs by flow cytometry at day 7. (C) 766 
Relative expression to Hprt of immunoregulatory genes in dLNs. cDNAs were pooled 767 
from three separate experiments. Values are expressed as mean ± SEM (n=6 mice per 768 
group), one representative of three independent experiments.  769 
Figure 5. Opn-induced tolerance is Treg cell-dependent. (A) Tolerance induction 770 
in diphtheria toxin (DT)-treated DEREG and control DEREG mice without DT 771 
injections. Controls (without tolerance) were DEREG mice pre-treated with PBS and 772 
subsequent allergy induction (white bars). (B) Eosinophil and total cell counts in 773 
BAL. (C) Numbers of Edu+CD3+CD4+ T cells per 25 x 104 OVA-stimulated dLN 774 
cells. (D) Lung inflammation and mucus secretion depicted in H&E (top) and PAS 775 
stained slides (bottom). Scale bar, 100 µm. (E) Levels of IL-5 and IL-13 in 776 
supernatants of OVA-stimulated dLN cells. Different wells of pooled mLN cells 777 
cultured in C and E. Values are expressed as mean ± SEM (n=6 mice per group), one 778 
representative of three independent experiments. 779 
Figure 6. Opn-induced tolerance increases pDC numbers favoring Treg cell 780 
accumulation. Mice received four doses of 120G8 pDC-depleting antibody or Ig 781 
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control i.p. on days -6, -5, -4 and -3, followed by tolerance induction for Treg cell 782 
generation with or without rOpn administration (for A). Also, allergic airway disease 783 
was subsequently induced on day 10 (for B and C). Control mice were pre-treated 784 
with PBS (in A) and sensitized with PBS (in B and C). (A) Representative 785 
percentages in flow cytometric plots and numbers of Treg cell (CD3+CD4+Foxp3+) 786 
accumulation in dLNs. (B) Eosinophil counts in BAL of allergic mice. (C) [3H]-787 
thymidine incorporation in OVA stimulated dLN cells. Quadruplicate wells of pooled 788 
mLN cells. Values are expressed as mean ± SEM (n=5 mice per group), one 789 
representative of three independent experiments. 790 
Figure 7. rOpn treatment of pDCs increases their suppressive activity against 791 
allergic airway disease. (A) [3H]-thymidine incorporation in co-cultures of DO11.10 792 
T cells pre-conditioned with OVA323-339 and rOpn treated pDCs with responder 793 
DO11.10 T cells Different wells of cultured cells. Values are expressed as mean ± 794 
SEM, one representative of three independent experiments. (B) Sorted pDCs pre-795 
conditioned in vitro with PBS or OVA or OVA/rOpn were adoptively transferred to 796 
recipient mice before the induction of allergic airway inflammation. Total and 797 
eosinophil cell count in BAL were evaluated (day 20). (C) Histological assessment of 798 
lung inflammation (H&E scoring) and lung mucus production (PAS score) and (D) 799 
levels of IL-4 and IL-13 in supernatants of OVA-stimulated mLN cells. Different 800 
wells of pooled mLN cells. Values are expressed as mean ± SEM (n=6-8 mice per 801 
group), one representative of three independent experiments. 802 
Figure 8. Opn SLAYGR motif boost tolerance by enhancing pDC recruitment to 803 
protect from allergy. (A) Numbers of dLN 7AAD–CD11c+B220+PDCA1+SiglecH+ 804 
pDCs after 40 hrs of tolerance induction with endograde-OVA i.n. along with rOpn or 805 
frOpn1, or frOpn2, or frOpn3, or PBS as in Fig. 3A. (B) OVA/frOpn-tolerance 806 
induction before allergic asthma for c-e. Control mice were pre-treated with PBS and 807 
allergy was subsequently induced (white bars). (C) AHR responses depicted as Penh 808 
in day 19. (D) Eosinophil cell count in BAL, histological assessment of lung 809 
inflammation (H&E scoring) and lung mucus production (PAS score) and numbers of 810 
T1ST2+CD4+ TH2 cells in mLNs. (E) Levels of IL-4, IL-5 and IL-13 in supernatants 811 
of OVA-stimulated mLN cells. Different wells of pooled mLN cells. Values are 812 
expressed as mean ± SEM (n=5, mice per group), one representative of three 813 
independent experiments.  814 
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Figure 9. Opn SLAYGR motif induces IFN-β production from pDCs. (A) 815 
Relative Ifnb expression to Hprt in pDCs conditioned in vitro with OVA/frOpn1 or 816 
frOpn3. (B) Levels of IFN-β in the supernatants of the same cultures. (C) Relative 817 
Ifnb expression to Hprt in pDCs in vitro conditioned with Derp1/frOpn1 compared to 818 
Derp1/frOpn3. (D) Representative percentages in flow cytometric plots and numbers 819 
of 7AAD–CD3–CD19–CD11c+PDCA-1+Siglec-H+IFN-βEYFP+ pDCs in dLNs of PBS-820 
treated or OVA-tolerized mice, and geometrical mean fluorescence intensity (gMFI) 821 
of IFN-β-expressing pDCs. (E) Relative Ifnb expression to Hprt in pDCs isolated 822 
from dLNs of PBS-treated or OVA/frOpn3- and OVA/frOpn1-tolerized mice. (F) 823 
Representative percentages in flow cytometric plots and numbers of total 7AAD–824 
CD3–CD19–CD11c+PDCA-1+Siglec-H+ IFN-βEYFP+, and gMFI of IFN-β-expressing 825 
pDCs in dLNs of mice treated with PBS or tolerized with MOG35-55/frOpn3 or 826 
MOG35-55/frOpn1. Mice were tolerized as in Fig. 3A. Values are expressed as mean ± 827 
SEM (n=6-8 mice per group), pooled data from three independent experiments.  828 
Figure 10. Opn/SLAYGLR induced IFN-β in pDCs renders them protective 829 
against allergic disease.  (A) Isolated Ifnar1+/+ pDCs were primed in vitro with OVA 830 
and frOpn1 or frOpn3 or with PBS and adoptively transferred to either Ifnar1+/+ or 831 
Ifnar–/– mice. Histological scores for airway inflammation and goblet cell hyperplasia 832 
in lung sections stained with H&E and PAS respectively and number of eosinophils 833 
present in BAL. (B) OVA-tolerance induction with blocking of IFNAR1 before 834 
allergic asthma (for C and D). Control mice were pre-treated with PBS and allergy 835 
was subsequently induced (white bars). (C) Numbers of eosinophils in BAL and (D) 836 
levels of IL-4 and IL-13 in supernatants of OVA-stimulated dLN cells. Different 837 
wells of pooled mLN cells. Values are expressed as mean ± SEM (n=4-5 in A and 838 
n=6 in B-D mice per group), one representative of three independent experiments. 839 
